The Journal of Urology
Volume 182, Issue 6 , Pages 2569-2577 , December 2009

Phosphatidylinositol-3-Kinase/Akt Signaling Pathway and Kidney Cancer, and the Therapeutic Potential of Phosphatidylinositol-3-Kinase/Akt Inhibitors

  • Camillo Porta

      Affiliations

    • Financial interest and/or other relationship with Bayer-Schering, Pfizer Oncology, Hoffman La Roche, Novartis and Wyeth.
    • Corresponding Author InformationCorrespondence: Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, Istituto Di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Piazzale C. Golgi 19, I-27100 Pavia, Italy (telephone: +39-0382-501355; FAX: +39-0382-526223)
    • ,
  • Robert A. Figlin

      Affiliations

    • Financial interest and/or other relationship with Wyeth.

Received 30 December 2008

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Study received institutional review board approval.

 See Editorial on page 2555.

 For another article on a related topic see page 2920.

PII: S0022-5347(09)02120-X

doi: 10.1016/j.juro.2009.08.085

The Journal of Urology
Volume 182, Issue 6 , Pages 2569-2577 , December 2009

Article Tools

* Image Usage & Resolution